Amidophosphoribosyltransferase Limits the Rate of Cell Growth-linked de Novo Purine Biosynthesis in the Presence of Constant Capacity of Salvage Purine Biosynthesis*

(Received for publication, April 3, 1997)

Takashi Yamaoka Dagger , Maki Kondo , Soichi Honda , Hiroyuki Iwahana , Maki Moritani , Setsuko Ii , Katsuhiko Yoshimoto and Mitsuo Itakura

From the Otsuka Department of Clinical and Molecular Nutrition, School of Medicine, The University of Tokushima, 3-18-15, Kuramoto-cho, Tokushima-city, 770, Japan

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES


ABSTRACT

Factors controlling relative flux rates of the de novo and salvage pathways of purine nucleotide biosynthesis during animal cell growth are not fully understood. To examine the relative role of each pathway for cell growth, three cell lines including CHO K1 (a wild-type Chinese hamster ovary fibroblast cell line), CHO ade -A (an auxotrophic cell line deficient of amidophosphoribosyltransferase (ATase), a presumed rate-limiting enzyme of the de novo pathway), and CHO ade -A transfected with human ATase cDNA (-A+hATase) resulting in 30-350% of the ATase activity of CHO K1, were cultured in purine-rich or purine-free media. Based on the enzyme activities of ATase and hypoxanthine phosphoribosyltransferase, the metabolic rate of the de novo and salvage pathways, the rate of cell growth (growth rate) in three cell lines under various culture conditions, and the effect of hypoxanthine infusion on the metabolic rate of the de novo pathway in rat liver, we concluded the following. 1) In -A+hATase transfectants, ATase activity limits the rate of the de novo pathway, which is closely linked with the growth rate. 2) Purine nucleotides are synthesized preferentially by the salvage pathway as long as hypoxanthine, the most essential source of purine salvage, can be utilized, which was confirmed in rat liver in vivo by hypoxanthine infusion. The preferential usage of the salvage pathway results in sparing the energy expenditure required for de novo synthesis. 3) The regulatory capacity of the de novo pathway (about 200%) was larger than that of the salvage pathway (about 20%) with constant hypoxanthine phosphoribosyltransferase activity.


INTRODUCTION

Purine nucleotides synthesized via de novo and salvage pathways are indispensable for cell growth through DNA and RNA syntheses and for the ATP energy supply. Interference of purine metabolism has thus been the target of antineoplastic drugs. However, it is unclear which of the two pathways is more important for the supply of purine nucleotides during cell growth. Purine nucleotide synthesis catalyzed by HPRT,1 the key enzyme of the purine salvage pathway, was reported to be more active than that catalyzed by ATase, the presumed rate-limiting enzyme of the de novo pathway, in many tissues and malignant cells (1, 2). The increased metabolic rate via the de novo pathway and ATase activity are, however, more strongly linked with cell growth and malignant transformation than the metabolic rate via the salvage pathway and HPRT activity (1, 3-7). To interpret this enigma, we investigated the mutual regulation of purine biosynthesis between the de novo and salvage pathways. The cDNA cloning of rat and human ATase (hATase) in our laboratory (8, 9), an ATase-deficient auxotrophic Chinese hamster ovary fibroblast cell line of CHO ade -A, and CHO ade -A transfected with hATase cDNA driven by the cytomegalovirus promoter (-A+hATase) enabled us to explore the rate-limiting property of ATase and to study the relationship between the two pathways in three cell lines in two purine-free or two purine-rich media relative to their contribution to cell growth. Furthermore, the effect of continuous Hx supplement on the metabolic rate of de novo synthesis was examined in rat liver.


EXPERIMENTAL PROCEDURES

Cell Culture

CHO K1 (wild type), CHO ade -A (10), which were gifts from Dr. David Patterson (Eleanor Roosevelt Institute for Cancer Research, CO), and -A+hATase were cultured at 37 °C in a CO2 incubator in the following media: (I) Ham's F-12 purine-rich medium containing 30 µM Hx with 10% fetal calf serum (FCS); (II) Ham's F-12 with 10% FCS treated with 1.25 mg (0.9 unit)/liter xanthine oxidase (XO) from buttermilk (Sigma) at 37 °C overnight, serving as a purine-free medium; (III) RPMI 1640 purine-free medium supplemented with 10% purine-free FCS; (IV) RPMI 1640 with 10% purine-free FCS and 30 µM Hx, serving as a purine-rich medium. In media I and IV, both the de novo and salvage pathways function in CHO K1 and -A+hATase, but only the salvage pathway functions in CHO ade -A. In media II and III, only the de novo pathway functions in CHO K1 and -A+hATase, and neither of the two pathways functions in CHO ade -A. Purine-free FCS was prepared by dialysis against 100-fold volumes of 0.9% NaCl with several exchanges of the dialysis solution at 4 °C for 24 h. The complete removal of Hx in media II and III was confirmed first by the disappearance of the Hx peak in the reversed phase high performance liquid chromatography analysis through a C18 column in 50 mM potassium phosphate buffer (pH 4.6) with a gradient from 0 to 5% of methanol for 20 min at the flow rate of 1.5 ml/min (data not shown), and second by no growth of CHO ade -A in these media (Table I).

Table I. Doubling time (h) of three cell lines under four culture conditions


 


a Both de novo and salvage pathways.
b Only de novo pathway.
c Only salvage pathway.
d Neither of the two pathways is functioning. (n), sample number; * p < 0.05; ** p < 0.01. HamF, Ham's F-12.

Transfection of CHO ade -A Cells with hATase cDNA

hATase cDNA (2.2 kilobase pairs) was inserted into the cloning site downstream of the cytomegalovirus promoter in pBCMGSNeo (14.5 kilobase pairs), which includes the replication origin of bovine papilloma virus (BPV) leading to 10-500 copies per cell in mammalian cells (11, 12). Five micrograms of this plasmid construct purified with the Plasmid Maxi Kit (QIAGEN, Hilden, Germany) were mixed with Transfectam solution (BioSepra Inc., Marlborough, MA) according to the manufacturer's protocol, and overlaid onto CHO ade -A (2 × 106 cells/90 mm tissue culture plate) in 5 ml of Opti-MEM (Life Technologies, Inc.). After the incubation at 37 °C for 6 h in a CO2 incubator, the DNA-containing medium was replaced with 10 ml of Ham's F-12 with 10% FCS and 800 µg/ml G418 to select transfectants with a high expression of the BPV vector (12). Several clones of -A+hATase were isolated after G418 selection for 7 days. To select clones with high ATase activity, -A+hATase was further cultured in Ham's F-12 + XO medium for 7 days. The culture in this purine-free medium positively selected the clones with high ATase activity associated with a high growth rate. The number of copies in transfectants was determined by Southern blot analysis (12-14).

Measurement of the Growth Rate

In a 35-mm dish, 1 × 105 cells were plated in 2 ml of medium and incubated at 37 °C in a CO2 incubator. After culturing for 24, 48, 72, or 96 h, the cells were counted after trypsinization with 0.1% trypsin and 0.02% EDTA, using an improved Neubauer hemocytometer. The doubling time (hours) of cultured cells was determined from cell counts during the logarithmic growth phase and its reciprocal was defined as the growth rate.

Determination of Metabolic Rates of de Novo and Salvage Pathways

The metabolic rates of de novo and salvage pathways were, respectively, determined by the incorporation of [14C]glycine and [14C]Hx in acid-soluble purines in comparison to the acid-insoluble fraction (15, 16). In a 90-mm tissue culture plate, 2 × 106 cells were plated. After the recovery of cell functions from plating by 18 h of culture, [14C]glycine or [14C]Hx was added to the medium at the final concentrations of 200 µM (185 kBq/ml) and 50 µM (37 kBq/ml), respectively. The cells were cultured in radioactive medium for 30 min, washed three times with 10 ml of ice-cold phosphate-buffered saline, and harvested with a rubber policeman. Purine ribonucleotides were extracted from the cells in 1 ml of 2 N perchloric acid at 100 °C for 60 min. The extract was cooled on ice for 5 min and centrifuged at 35,000 × g at 4 °C for 5 min. The supernatant was applied to a column (0.5 × 2 cm) of AG-50W-X8 (Bio-Rad) equilibrated with 0.1 N HCl. After washing with 5 ml of 1 N HCl, the acid-soluble purines were eluted with 5 ml of 6 N HCl, and counted in a scintillation counter. The amount of purines was determined by the absorbance of the eluate at 260 nm. To measure the incorporation of [14C]glycine in protein, the acid-insoluble precipitate after the last centrifugation was washed three times with 10% trichloroacetic acid, dissolved in 200 µl of 0.3 N NaOH, and the radioactivity was counted in a scintillation counter. The protein concentrations were assayed by Bradford's (17) method. The metabolic rate of the de novo pathway was defined as the ratio of the dpm incorporated into purines per 1 OD at 260 nm to the disintegrations/min incorporated into 1 mg of protein, while the rate of the salvage pathway was defined as the disintegrations/min incorporated into purines per 1 OD at 260 nm.

Assay of ATase and HPRT Activities

Cells detached with trypsin and EDTA were centrifuged at 500 × g at 4 °C for 5 min. The cell pellet was washed with 1 ml of phosphate-buffered saline in a microtube. After centrifugation again at 500 × g at 4 °C for 5 min, the cell pellet was resuspended in 100 µl of sonication buffer containing 50 mM potassium phosphate buffer (pH 7.4), 5 mM dithiothreitol, 100 µg/ml phenylmethylsulfonyl fluoride, and 2 µg/ml aprotinin. Sonication was performed by the Sonifier 250 (Branson Ultrasonics Corp. Danbury, CT) with a 90% duty cycle at the output dial setting of 3 for 15 s. These sonication conditions were selected because they yielded the highest extraction of ATase activity (data not shown). The supernatant after the centrifugation at 35,000 × g at 4 °C for 20 min was used for the assay of both ATase and HPRT. The complete breakdown of the cell membrane was confirmed by microscopic observation of the pellet.

The method of ATase assay was the same as reported previously (18). In brief, the cell lysate was incubated in 50 mM potassium phosphate buffer (pH 7.4) containing 5 mM 5-phosphoribosyl 1-pyrophosphate (PRPP), 5 mM MgCl2, 1 mM dithiothreitol, and 5 mM [14C]glutamine (5.55 kBq/µmol) at 37 °C for 1 h. Formed [14C]glutamate was separated from [14C]glutamine by high voltage paper electrophoresis at 800 W for 15 min and counted in a scintillation counter. The PRPP-dependent hydrolysis of glutamine to glutamate was regarded as representing ATase activity.

To assay HPRT activity, the cell lysate was incubated in 50 mM Tris-Cl (pH 7.4) containing 1.5 mM PRPP, 5 mM MgCl2, and 5 mM [14C]Hx (27.8 kBq/µmol) in the assay volume of 50 µl at 37 °C for 20 min. To stop the reaction, the assay mixture was cooled on ice, and 5 µl of 0.5 M EDTA were added. The formed [14C]IMP was separated from [14C]Hx by high voltage paper electrophoresis at 800 W for 15 min, and the [14C]IMP spot on the filter paper was cut out under a UV lamp. The radioactivity of this spot was counted in a scintillation counter.

Northern Blot Analysis of HPRT

Because the HPRT activity in CHO fibroblasts was nearly constant under all of the experimental conditions in this study (see Table VI), mRNA levels of HPRT were examined by Northern blot analysis using rat HPRT cDNA as a probe. For the preparation of the probe, total RNA was extracted from rat 3Y1 fibroblasts by ISOGEN (Nippon Gene, Osaka, Japan) and reverse-transcribed to cDNA with the avian myeloblastosis virus reverse transcriptase first-strand cDNA synthesis kit (Life Sciences, Inc., St. Petersburg, FL). Rat HPRT cDNA in 697 base pairs (a sense primer; 5'-GACCGGATCCGTCATGTCGACCCT-3' and an antisense primer; 5'-CTTGTGAATTCAACTTGCCGCTGT-3') and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA in 621 base pairs (a sense primer; 5'-TGGCGTCTTCACCACCATGGAGAA-3', and an antisense primer; 5'-TTGTCATTGAGAGCAATGCCAGCC-3') were amplified by the polymerase chain reaction using the primer pairs shown in parentheses and cloned into a pCR II vector (Invitrogen Corp., San Diego, CA). The base sequence of the cloned polymerase chain reaction products was confirmed to be identical to the reported sequence by the fluorescent automated DNA sequencer (ABI 377, Perkin-Elmer, Division of Applied Biosystems, Foster City, CA). Northern blot analysis was performed by the standard method (14).

Table VI. HPRT activity of three cell lines under four culture conditions


Cultured cells Culture media
(I) HamFa (II) HamF+ XO (III) RPMI (IV) RPMI+ Hx

nmol/h/107 cells
CHO K1 3060  ± 175 3100  ± 85 2975  ± 90 2949  ± 100
CHO ade -A 2995  ± 103 2955  ± 40 2931  ± 127 2996  ± 72
-A+hATase 2990  ± 81 2946  ± 102 2953  ± 67 2999  ± 72

a HamF, Ham's F-12.

Animal Study

To examine the effect of the continuous supply of Hx on the metabolic rate of the de novo pathway in rat liver in vivo, 5.0 µmol/200 g of body weight/12 h of Hx were continuously infused for 12 h via an intravenous cannula into the jugular vein of 8-week-old male Wistar rats according to the method previously published (19). Thirty minutes before the end of infusion, 185 kBq/44-45 nmol [14C]glycine was administered intravenously. The rat liver was sampled exactly 30 min after the injection by freeze-clamping, and the liver sample pulverized under liquid nitrogen was placed in 4 ml of 2 N perchloric acid. The metabolic rate of the de novo pathway was then determined by the procedures mentioned above. To examine the effect of the continuous supply of Hx on the increased rate of the de novo pathway by glucagon in liver (19), 0.5 mg of glucagon/200 g of body weight/12 h with or without Hx of 5.0 µmol/200 g of body weight/12 h was similarly infused, and the metabolic rate of the de novo pathway in liver was determined. The stimulative effect of glucagon on the de novo purine synthesis in liver has been reported (19, 20) and is applied to glucagon and insulin therapy for acute liver failure.

Statistical Analysis

All data were presented as means ± S.D. The number of repetitive determinations for each value or point is as follows: six to eight for Table I, three for Table IV, three to four for Tables V and VI and Fig. 3, and two to four for Figs. 1 and 2. For comparison of data, Student's paired or unpaired t test was used. A probability of less than 0.05 was considered statistically significant.

Table IV. Metabolic rates of de novo and salvage pathways of three cell lines



Table V. ATase activity of three cell lines under four culture conditions


Cultured cells Culture media
(I) HamFa (II) HamF+ XO (III) RPMI (IV) RPMI+ Hx

nmol/h/107 cells
CHO K1 345  ± 12 286  ± 26 259  ± 22 304  ± 17
CHO ade -A NDb ND ND ND
-A+hATase 321  ± 18 275  ± 22 250  ± 16 318  ± 21

a HamF, Ham's F-12.
b ND, not detectable.


Fig. 3. The relationship between the growth rate and the ATase activity (A) or the HPRT activity (B). The growth rate and the enzyme activities of ATase and HPRT were determined for the three cell lines CHO K1, CHO ade -A, and the -A+hATase clone stably expressing ATase activity at the same level as CHO K1. Because ATase activity is absent in CHO ade -A cells, the total number of data points in panel A was 8, and that in panel B was 12.
[View Larger Version of this Image (13K GIF file)]


Fig. 1. The correlation between the ATase activity and the metabolic rate of the de novo pathway or the growth rate for six clones of -A+hATase. In six transfectants of CHO ade -A with human ATase cDNA, the ATase activity, the metabolic rate of the de novo pathway, and the growth rate were determined in Ham's F-12, a purine-rich medium. The hatched bar represents the range of ATase activity in wild-type CHO K1 cells.
[View Larger Version of this Image (29K GIF file)]


Fig. 2. The time course for the number of copies of the transgene, the ATase activity, the metabolic rate of the de novo pathway, and the growth rate in one clone of -A+hATase. The transfectant of CHO ade -A with the lowest ATase expression was placed in a long term culture in Ham's F-12 with xanthine oxidase, a purine-free medium. In this medium, cells with a higher ATase activity grew more rapidly, and were positively selected. For Southern blot analysis, a BamHI fragment (2.7 kilobase pairs) of pBCMGSNeo including hATase cDNA was used as the probe and an indicator of copy number. From a comparison with the radioactive intensity of indicator bands, the number of copies of the transgene in this clone increased from 10 to 40 during 30 passages, plotted on the abscissa.
[View Larger Version of this Image (33K GIF file)]


RESULTS

Effect of Purine Bases on the Growth Rate

To determine the necessary concentrations of purine bases for the maximal growth rate of CHO fibroblasts, ATase-deficient CHO ade -A cells were cultured in purine-free RPMI medium supplemented with Hx, adenine, or guanine at various final concentrations of up to 50 µM. Of the three purine bases, Hx most effectively increased the growth rate, while no cell growth was observed with guanine as the only source of the salvage pathway. Because Hx at a concentration of more than 30 µM increased the growth rate of CHO ade -A fibroblasts to the maximal plateau level, and because adenine in addition to 30 µM Hx inversely decreased the growth rate (data not shown), it was considered that Hx at a concentration over 30 µM drives the flux through the salvage pathway at its maximum in CHO ade -A fibroblasts. These observations demonstrated that Hx is the principal source for the salvage pathway in CHO ade -A fibroblasts.

Characterization of -A+hATase

Six clones of A+hATase obtained after G418 selection in purine-free medium were cultured in purine-rich medium. The level of ATase expression among these clones ranged from about 30 to 350% of that in CHO K1. The level of ATase expression (plotted on the x axis) strongly correlated with the metabolic rate of the de novo pathway and with the growth rate (both plotted on the y axis) (Fig. 1), with correlation formulas of y = 0.00047x - 0.53 (r = 0.83) and y = 0.0045x - 3.8 (r = 0.95), respectively. The metabolic rate of the de novo pathway also strongly correlated with the growth rate (r = 0.93, data not shown). It is notable that the doubling time of the -A+hATase clone with the highest ATase expression among the 6 transfectants examined was shortened down to 10.5 h, i.e. 9.5 × 10-2/h of growth rate, from the initial 16.8 h for wild-type CHO K1 cells. This correlation does not appear to be saturated even at the highest ATase activity of 350% of that in CHO K1. These results obtained from -A+hATase clearly demonstrated that ATase is a rate-limiting enzyme of the de novo pathway. The levels of ATase activity in -A+hATase clones closely correlated with their growth rate even under conditions where purine nucleotide synthesis by means of the salvage pathway was available in purine-rich medium (Fig. 1).

The growth rate of -A+hATase clones gradually increased during their positive selection in purine-free medium. The -A+hATase clone with the lowest ATase activity was cultured in purine-free medium up to passage number 30, where its growth rate reached the maximal plateau. The number of copies of the hATase transgene, the ATase activity, the metabolic rate of the de novo pathway, and the growth rate were periodically determined up to passage number 30 (Fig. 2). With the gradual increase in the number of copies of the transgene from 10 to 40 per cell, as shown by the increase in the intensity of the radioactive bands in Southern blot analysis, the ATase activity, the metabolic rate of the de novo pathway, and the growth rate increased in parallel, and all of these simultaneously reached the plateau level at passage number 24. The rate-limiting quality of ATase for the de novo pathway was thus demonstrated both by the correlation of ATase activity with the metabolic rate of the de novo pathway among six clones of -A+hATase (Fig. 1) and during the long term culture of one clone of -A+hATase (Fig. 2). In addition to the rate-limiting property of ATase for the de novo synthesis, these observations demonstrated that ATase activity closely correlated with the growth rate under these conditions.

Doubling Time and Growth Rate in Three Cell Lines under Four Culture Conditions

Three cell lines including CHO K1, CHO ade -A, and the -A+hATase clone stably expressing ATase activity at the same level as CHO K1 were used. The doubling time and the growth rate of these three lines of CHO fibroblasts under the various culture conditions tested in this study are summarized in Tables I and II, respectively. In purine-free medium, CHO ade -A did not proliferate at all. The growth rate under conditions where both purine biosynthetic pathways were functioning were significantly higher than those under conditions where either the de novo or the salvage pathway was functioning. The difference in the growth rate between the two different conditions was calculated and presented as the increase in the growth rate in Table III. The independent contribution of the de novo pathway in the absence of the salvage pathway was significantly larger than that of the salvage pathway in the absence of the de novo pathway (4.2 versus 3.4 × 10-2/h). The additive contribution of the de novo pathway to the salvage pathway was also significantly greater than that of the salvage pathway to the de novo pathway (1.8 versus 1.0 × 10-2/h). The growth rate of 5.2 × 10-2/h achieved by the participation of both pathways was lower than the sum of 7.6 × 10-2/h obtained by adding 4.2 × 10-2/hr through the de novo pathway alone and 3.4 × 10-2/h through the salvage pathway alone. To interpret the mechanism of this nonadditive antagonism, the metabolic rates of both pathways and the enzyme activities of ATase and HPRT, the key enzymes of the de novo and the salvage pathways, respectively, were determined.

Table II. Growth rate (× 10-2/h) of three cell lines under four culture conditions

See Table I for an explanation of symbols and letters. The reciprocal of doubling time was defined as the growth rate.

Table III. Contribution of purine biosynthetic pathway(s) to the increase in the growth rate

See Table I for an explanation of symbols and letters. The difference of the growth rate between two conditions was defined as the increase in the growth rate.

Metabolic Rates of de Novo and Salvage Pathways in Three Cell Lines under Four Culture Conditions

To explain the antagonism between two purine biosynthetic pathways, the metabolic rates of the de novo and the salvage pathways were assayed by the incorporation of [14C]glycine and [14C]Hx, respectively (Table IV). When both pathways were functioning, the metabolic rate of the de novo pathway was suppressed by -69 and -64% in CHO K1 and -A+hATase, respectively, compared with that when only the de novo pathway was functioning. On the other hand, the salvage pathway activity was modestly suppressed through the additive availability of the de novo pathway only by -17 and -24% in CHO K1 and -A+hATase, respectively, compared with that when only the salvage pathway was functioning. These results indicate that purine nucleotides are synthesized preferentially via the salvage pathway as long as CHO fibroblasts are allowed to use the salvage pathway. Moreover, the preferential utilization of the salvage pathway with the concomitant suppression of the de novo pathway led to a large reserve capacity of de novo synthesis. From a comparison between the metabolic rates of CHO K1 cultured in Ham's F-12 and Ham's F-12 + XO, the reserve capacity of de novo synthesis of CHO K1 in Ham's F-12 was estimated at 218% ((0.89 - 0.28)/0.28 × 100), whereas the reserve capacity of the salvage pathway of CHO K1 in Ham's F-12, compared with CHO ade -A in Ham's F-12, was estimated at only 20% ((2349 - 1962)/1962 × 100).

ATase and HPRT Activities in Three Cell Lines under Four Culture Conditions

The enzyme activities of ATase and HPRT under four culture conditions were summarized in Table V for the ATase of CHO K1 and the -A+hATase clone (no ATase activity was detected in CHO ade -A), and Table VI for the HPRT of CHO K1, CHO ade -A, and the -A+hATase. In both CHO K1 and -A+hATase, the ATase activity was higher when both pathways were functioning than that when only the de novo pathway was functioning. ATase activity under eight experimental combinations of two cell lines and four culture conditions strongly correlated with the growth rate (Fig. 3A). In contrast to ATase activity, HPRT activity remained at a constant level irrespective of 12 different experimental conditions. Even when the growth of CHO ade -A fibroblasts was arrested by culturing them in purine-free medium, the HPRT activity changed only by -2%, compared with the other growing conditions examined. The HPRT activity thus remained at a constant level and did not correlate with the growth rate (Fig. 3B).

Northern Blot Analysis of HPRT mRNA

Although little change of HPRT activity was observed in CHO fibroblasts during growth arrest (Table VI), Northern blot analysis of HPRT showed an obvious decrease in growth-arrested CHO ade -A in purine-free medium (Fig. 4). The stability of the HPRT enzyme activity despite its decreased mRNA is probably due to the long half-life of the HPRT protein rather than constant transcriptional activity or mRNA stability.


Fig. 4. Northern blot analysis of HPRT. Because the growth of CHO ade -A was arrested in Ham's F-12 + XO, the decrease in the GAPDH mRNA level in this lane is regarded as the decrease in GAPDH transcription rather than an insufficient amount of total RNA applied to this lane.
[View Larger Version of this Image (24K GIF file)]

Animal Study

Hx infusion through a cannula into the jugular vein of 8-week-old male Wistar rats for 12 h suppressed the metabolic rate of the de novo pathway from 0.19 ± 0.02 (n = 4) with saline infusion to 0.09 ± 0.02 (n = 4), or -53%. Furthermore, the increased metabolic rate of the de novo pathway by 295% by glucagon infusion (0.56 ± 0.05, n = 5) was completely canceled by the concomitant infusion of Hx (0.17 ± 0.06, n = 4). Thus, the preferential utilization of the salvage pathway with the suppressed metabolic rate of the de novo pathway observed in CHO fibroblasts was ascertained by the decrease in the metabolic rate of the de novo pathway in liver during Hx infusion in this animal study. Like CHO K1 fibroblasts cultured in Ham's F-12, the large reserve capacity of de novo synthesis in rat liver before glucagon infusion was estimated to be as high as 195% ((0.56 - 0.19)/0.19 × 100).


DISCUSSION

Effect of Purine Bases on the Growth Rate

Hx, guanine, and adenine incorporated into cells are converted to IMP, GMP, and AMP, respectively, by the catalysts of HPRT and adenine phosphoribosyltransferase. In cells, IMP is converted to GMP and AMP as required. However, interconversion between GMP and AMP through IMP is often insufficient for a balance of these two purine nucleotides (21). Therefore, generally Hx is the most important source, and HPRT is the most important enzyme for the salvage pathway. Indeed, of the three purine bases, Hx had the greatest effect on the growth rate of CHO ade -A fibroblasts. Hx at a concentration of more than 30 µM increased the growth rate of CHO ade -A fibroblasts to its maximum, but a further addition of adenine decreased the maximal growth rate. In mitogen-stimulated human T cells and a human B lymphoblast cell line of WI-L2, under the inhibition of de novo synthesis with aminopterin, the addition of 30 µM Hx was reported to restore the growth rate and DNA and protein syntheses to normal levels (22). The inhibitory effect of adenine observed in our study is compatible with the reported inhibitory effect of adenine and adenosine on the growth of WI-L2, although the mechanism is unknown (23).

Characterization of -A+hATase

The molecular cloning of mammalian ATase made it possible to test the hypothesis of the rate-limiting property of ATase for de novo synthesis utilizing an ATase-deficient auxotrophic cell line of CHO ade -A. After the transfection of CHO ade -A fibroblasts with hATase cDNA, the ATase activity, the metabolic rate of the de novo pathway, and the growth rate were closely correlated for six clones of -A+hATase (Fig. 1) and for different passage points of one clone of -A+hATase, with an increase in ATase activity along with its passage (Fig. 2). These results for the first time provided molecular evidence that ATase limits the rate of the de novo purine synthetic pathway. ATase was linked with the growth rate even in a purine-rich medium where the salvage pathway was also functioning. It should be noted that the increase in the growth rate was not saturated even with an ATase activity as high as 350% of the level in CHO K1 (Fig. 1). The doubling time of the -A+hATase clone with the highest ATase expression was as short as 10.5 h. Such rapid cell growth was hardly observed even in undifferentiated neoplasms. ATase may function as a progression factor for malignant cells, a transforming factor, or a product of proto-oncogene. The transforming ability of ATase could not, however, be examined in our system because we used already transformed CHO fibroblasts and the BPV vector with the low oncogenic potential (13). Furthermore, the ATase activity, the metabolic rate of the de novo pathway, and the growth rate of -A+hATase gradually increased in purine-free medium with an increasing number of copies of the transgene (Fig. 2). The number of copies of the BPV vector was reported to be maintained constant in each transfectant, although it differed for the various transfectants (12, 13). The number of copied of the BPV vector in one transfectant in this study was, however, demonstrated to gradually increase from 10 to 40 per cell during its maintenance through 24 passages in the purine-free medium. The purine-free medium was considered to have served as a positive selective pressure for the high ATase activity associated with the high growth rate.

The Energy-saving Regulation of Metabolic Rates via Two Synthetic Pathways

Although the de novo pathway contributed to the increase in the growth rate more significantly than the salvage pathway, an antagonism between the two pathways was observed when both pathways were functioning (Table III). The determination of the metabolic rates of both pathways under various conditions revealed that the inhibition of the de novo pathway by the salvage pathway is much greater than that of the salvage pathway by the de novo pathway (Table IV). Purine nucleotides were thus shown to be synthesized preferentially via the salvage pathway with the concomitant suppression of de novo synthesis, as long as the salvage pathway can be utilized. This regulation in CHO fibroblasts results in a sparing of the energy expenditure inevitably required for the de novo pathway, in which many ATP molecules are required for purine nucleotide synthesis.

Regulation of ATase and HPRT Activities

ATase expression is regulated by means of the purine repressor in bacteria (24, 25). The purine repressor with a purine corepressor, either Hx or guanine, specifically binds its 16-base pair operator site, and suppresses ATase expression. Through this mechanism, purine nucleotides in bacteria are synthesized preferentially via the salvage pathway with the concomitant suppression of de novo synthesis, as long as substrates for the salvage pathway are available. To determine whether a repressor-type mechanism is functioning in CHO fibroblasts, the enzyme activities of ATase and HPRT were assayed (Tables V and VI). Because ATase and HPRT are fully activated under the assay conditions in this study, the enzyme activities directly reflect the amount of the corresponding enzymes. Although the metabolic rate of the de novo pathway was distinctly suppressed when both pathways were functioning (Table IV), the ATase activity under this condition was even higher than that when only the de novo pathway was functioning (Table V). The mechanism by which the salvage pathway inhibits the de novo pathway is thus not due to the decrease in ATase expression, unlike the repressor mechanism in bacteria. The suppression of the metabolic rate of the de novo pathway by the salvage pathway probably results from 1) the increased feedback inhibition of ATase by purine nucleotides produced via the salvage pathway and 2) the consumption of PRPP, a common substrate for both pathways and an activator of ATase, through the salvage pathway. The close correlation of ATase expression with the growth rate irrespective of the activity of the salvage pathway (Fig. 3A) suggested that ATase expression is linked with the signal for cell growth rather than the concentrations of PRPP and purine nucleotides.

Because the HPRT activity, unlike the ATase activity, was nearly constant (Table VI), the modest suppression of the salvage pathway by the de novo pathway (Table IV) is not due to a decrease in HPRT expression, but is presumably due to PRPP consumption via the de novo pathway. A large consumption of PRPP by de novo synthesis was suggested by the 4-fold increase in PRPP concentration in murine leukemia cells treated with 6-mercaptopurine and methotrexate to inhibit de novo synthesis (26).

Regulation of HPRT Activity

Even after the growth arrest of CHO ade -A fibroblasts in purine-free medium for 48 h, HPRT activity did not decrease (Table VI), while the HPRT mRNA level was remarkably decreased (Fig. 4), suggesting that HPRT is a relatively stable protein. In human peripheral lymphocytes, the half-life of the HPRT protein was reported to be more than 48 h, in contrast to an estimated half-life of HPRT mRNA of only 5.1 h (27).

Animal Study

Intravenous infusion of Hx to 8-week-old male Wistar rats for 12 h suppressed the metabolic rate of the de novo pathway by -53% and canceled its increase by glucagon stimulation. Thus, the preferential utilization of the salvage pathway with the suppression of the de novo pathway was observed not only in CHO fibroblasts, but also in rat liver in vivo. A preference for the salvage pathway is probably due to the following factors: 1) In many tissues and cultured cells, the specific activity of HPRT is much higher than that of ATase (1). For example, the ratio of HPRT activity to ATase activity is 6.6 in rat liver (2), or about 10 in CHO fibroblasts (Tables V and VI). 2) The affinity of HPRT to PRPP, a substrate shared by both enzymes, is markedly higher than that of ATase; the Km of HPRT to PRPP is 4 to 40 µM and that of ATase is 400-900 µM (1, 2, 7). 3) Purine nucleotides produced via the salvage pathway allosterically inhibit ATase, whereas HPRT is not affected. It was reported that physiological concentrations of Hx strongly suppress de novo synthesis in human bone marrow in vivo (28).

Although the salvage pathway is preferentially utilized, its reserve capacity for purine synthesis during cell growth was small because of the nearly constant activity of HPRT (Table VI). In contrast, the reserve capacity of de novo synthesis for changing its metabolic rate was relatively high, and could be attained through several regulatory mechanisms including the allosteric activation or inhibition of ATase activity (29, 30), the cell cycle-dependent expression of the ATase gene (31), and the relatively short half-life of the ATase protein.2 Resting human T lymphocytes were reported to meet their metabolic demands via the salvage pathway except during cell growth, while intact de novo synthesis is essential for the proliferation of phetohemagglutinin-stimulated T lymphocytes (32). The large capacity of de novo synthesis has been shown in patients with Lesch-Nyhan's syndrome (complete deficiency of HPRT) and in cultured cells from patients with this syndrome. Although these patients are affected with severe lesions in the central nervous system, the growth and development of other organs are almost normal due to compensation by de novo synthesis and, in part, the salvage pathway by adenine phosphoribosyltransferase. Fibroblasts from these patients showed a normal PRPP concentration and nucleotide pools were compensated by an increased de novo synthesis (30). Also, the proliferation of T lymphocytes from the patients in response to mitogenic and antigenic stimulation was normal (33). In the leukocytes from two gouty patients affected with a partial deficiency of HPRT, de novo synthesis was accelerated to more than 13 times that of normal controls (34).

The regulatory factors of ATase gene expression, which is essential for the high capacity control of de novo synthesis, include tissue specificity (1), cell cycle (31), cell density,2 malignant transformation (1, 2, 6, 7), and differentiation (35). Biochemical and molecular biological studies are underway in our laboratory to investigate the regulatory mechanism of ATase gene expression and its activity.

In conclusion, the following concepts were supported in this study using CHO fibroblasts and rat liver. First, the ATase activity in CHO transfectants with hATase cDNA, which ranges from 30 to 350% of that of wild-type CHO K1, limits the metabolic rate of de novo synthesis and strongly correlates with the growth rate. This was confirmed by a parallel increase in the ATase activity, the metabolic rate of the de novo pathway, and the growth rate of one CHO transfectant with hATase cDNA relative to its passage in purine-free medium. Second, purine nucleotides are synthesized preferentially through the salvage pathway not only in cultured fibroblasts, but also in rat liver in vivo, as long as a source of purine salvage is available, with the concomitant suppression of the de novo pathway. This mechanism results in the sparing of energy expended by de novo synthesis. Last, the complex regulatory mechanisms of the gene expression and enzyme activity of ATase compared with the relatively constant enzyme activity of HPRT provide for a larger reserve capacity of de novo synthesis than of salvage synthesis, and reflect the molecular basis for meeting the metabolic demands required for the increased rate of cell growth.


FOOTNOTES

*   This study was supported in part by a grant from the Otsuka Pharmaceutical Factory Inc.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    To whom correspondence should be addressed: Tel.: 81-886-33-7098; Fax: 81-886-31-9476; E-mail: itakura{at}nutr.med.tokushimau.ac.jp.
1   The abbreviations used are: HPRT, hypoxanthine phosphoribosyltransferase; ATase, amidophosphoribosyltransferase; -A+hATase, CHO ade -A expressing human ATase; BPV, bovine papilloma virus; CHO, Chinese hamster ovary; FCS, fetal calf serum; Hx, hypoxanthine; PRPP, 5-phosphoribosyl 1-pyrophosphate; XO, xanthine oxidase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
2   T. Yamaoka, M. Kondo, S. Honda, H. Iwahana, M. Moritani, S. Ii, K. Yoshimoto, and M. Itakura, unpublished data.

REFERENCES

  1. Natsumeda, Y., Prajda, N., Donohue, J. P., Glover, J. L., and Weber, G. (1984) Cancer Res. 44, 2475-2479 [Abstract]
  2. Weber, G., Jayaram, H. N., Pillwein, K., Natsumeda, Y., Reardon, M. A., and Zhen, Y. S. (1987) Adv. Enzyme Regul. 26, 335-352 [CrossRef][Medline] [Order article via Infotrieve]
  3. Alexiou, M., and Leese, H. J. (1992) Development 114, 185-192 [Abstract]
  4. Rowe, P. B., and McEwen, S. E. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 7333-7336 [Abstract]
  5. Bardot, V., Dutrillaux, A. M., Delattre, J. Y., Vega, F., Poisson, M., Dutrillaux, B., and Luddioni, C. (1994) Br. J. Cancer 70, 212-218 [Medline] [Order article via Infotrieve]
  6. Natsumeda, Y., Lui, M. S., Emrani, J., Faderan, M. A., Reardon, M. A., Eble, J. N., Glover, J. L., and Weber, G. (1985) Cancer Res. 45, 2556-2559 [Abstract]
  7. Weber, G., Lui, M. S., Natsumeda, Y., and Faderan, M. A. (1983) Adv. Enzyme Regul. 21, 53-69 [Medline] [Order article via Infotrieve]
  8. Iwahana, H., Yamaoka, T, Mizutani, M, Mizusawa, N., Ii, S., Yoshimoto, K., and Itakura, M. (1993) J. Biol. Chem. 268, 7225-7237 [Abstract/Free Full Text]
  9. Iwahana, H., Oka, J., Mizusawa, N., Kudo, E., Ii, S., Yoshimoto, K., Holmes, E. W., and Itakura, M (1993) Biochem. Biophys. Res. Commun. 190, 192-200 [CrossRef][Medline] [Order article via Infotrieve]
  10. Oates, G., and Patterson, D. (1977) Somatic Cell Genet. 3, 561-577 [Medline] [Order article via Infotrieve]
  11. Karasuyama, H., Kudo, A., and Melchers, F. (1990) J. Exp. Med. 172, 969-972 [Abstract]
  12. Niwa, H., Yamamura, K., and Miyazaki, J. (1991) Gene (Amst.) 108, 193-200 [CrossRef][Medline] [Order article via Infotrieve]
  13. Uemura, N., Ozawa, K., Tojo, A., Takahashi, K., Okano, A., Karasuyama, H., Tani, K., and Asano, S. (1992) Blood 180, 3198-3204
  14. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  15. Tsuchiya, M., Yoshikawa, H., Itakura, M., and Yamashita, K. (1990) Am. J. Physiol. 258, C841-C848 [Abstract/Free Full Text]
  16. Boss, G. R., and Erbe, R. W. (1982) J. Biol. Chem. 257, 4242-4247 [Abstract/Free Full Text]
  17. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254 [CrossRef][Medline] [Order article via Infotrieve]
  18. Itakura, M., and Holmes, E. W. (1979) J. Biol. Chem. 333, 999-1003
  19. Itakura, M., Maeda, N., Tsuchiya, M., and Yamashita, K. (1987) Am. J. Physiol. 253, E684-E690 [Abstract/Free Full Text]
  20. Des Rosiers, C., Lalanne, M., and Willemot, J. (1980) Can. J. Biochem. 58, 599-606 [Medline] [Order article via Infotrieve]
  21. Zoref-Shani, E., and Sperling, O. (1980) Enzyme 25, 413-418 [Medline] [Order article via Infotrieve]
  22. Thompson, L. F. (1985) J. Immunol. 134, 3794-3797 [Abstract/Free Full Text]
  23. Hershfield, M. S., Snyder, F. F., and Seegmiller, J. E. (1977) Science 197, 1284-1287 [Medline] [Order article via Infotrieve]
  24. Rolfes, R. J., and Zalkin, H. (1988) J. Biol. Chem. 263, 19653-19661 [Abstract/Free Full Text]
  25. Schumacher, M. A., Choi, K. Y., Lu, F., Zalkin, H., and Brennan, R. G. (1995) Cell 83, 147-155 [Medline] [Order article via Infotrieve]
  26. Liliemark, J., Pettersson, B., and Peterson, C. (1992) Leuk. Res. 16, 275-280 [Medline] [Order article via Infotrieve]
  27. Steen, A. M., Sahlen, S., and Lambert, B. (1991) Biochim. Biophys. Acta 1088, 77-85 [Medline] [Order article via Infotrieve]
  28. King, M. E., Honeysett, J. M., and Howell, S. B. (1983) J. Clin. Invest. 72, 965-970 [Medline] [Order article via Infotrieve]
  29. Becker, M. A., and Kim, M. (1987) J. Biol. Chem. 262, 14531-14537 [Abstract/Free Full Text]
  30. Becker, M. A., Losman, M. J., and Kim, M. (1987) J. Biol. Chem. 262, 5596-5602 [Abstract/Free Full Text]
  31. Iwahana, H., Honda, S., Tsujisawa, T., Takahashi, Y., Azuma, K., Katashima, R., Yamaoka, T., Moritani, M., Yoshimoto, K., and Itakura, M. (1994) Biochim. Biophys. Acta 1261, 369-380
  32. Fairbanks, L. D., Bofill, M., Ruckemann, K., and Simmonds, H. A. (1995) J. Biol Chem. 270, 29682-29689 [Abstract/Free Full Text]
  33. Allison, A. C., Hovi, T., Watts, R. W., and Webster, A. D. (1975) Lancet 7946, 1179-1183
  34. Brosh, S., Boer, P., Kupfer, B., deVries, A., and Sperling, O. (1976) J. Clin. Invest. 58, 289-297 [Medline] [Order article via Infotrieve]
  35. Ahmed, N., and Weidemann, M. J. (1994) Leuk. Res. 18, 441-451 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.